Head to head
Efinopegdutide against Survodutide
Two GLP-1 and glucagon dual agonists developed with the liver in mind. Efinopegdutide has been randomised against semaglutide on liver fat; survodutide has not, so their evidence is not the same shape even though their mechanism is.
Column A
EfinopegdutideEfinopegdutide (MK-6024), GLP-1 and glucagon receptor dual agonist
Beat semaglutide on liver fat in a randomised head to head, cutting it 72.7 percent against 42.3 percent, while the weight difference was not significant. Adding glucagon does something to the liver that GLP-1 alone does not.
Column B
SurvodutideSurvodutide (GLP-1 / glucagon dual agonist)
An investigational once-weekly GLP-1 and glucagon receptor dual agonist studied for obesity and metabolic liver disease.
Side by side, on the facts we can check
| Attribute | Efinopegdutide | Survodutide |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | Investigational. Not approved. Licensed to Merck, originally from Hanmi, and previously carried Johnson and Johnson and Hanmi identifiers. | Investigational, not FDA-approved |
| Half-life | Long-acting, dosed once weekly by subcutaneous injection. No specific half-life figure was resolved in the sources loaded. | ~6 days |
| Molecular weight | Peptide conjugated to a long-acting carrier. No mass asserted; no source loaded states one. | ~4,900 Da |
| Mechanism | A co-agonist at the GLP-1 and glucagon receptors, built on a long-acting Fc-based scaffold. GLP-1 receptor agonism reduces food intake and improves glycaemic control in the usual way. Glucagon receptor agonism raises hepatic fatty acid oxidation and reduces de novo lipogenesis, and also increases energy expenditure, which is the intended mechanism for the liver fat effect. The glycaemic risk of glucagon agonism is the reason these drugs are balanced rather than glucagon-dominant. | Agonizes both GLP-1 and glucagon receptors, combining appetite suppression and improved glucose handling with increased energy expenditure and hepatic fat reduction. |
| Human studies cited | 3 | 3 |
| Legal status, US | Investigational, not approved | Investigational, not approved |
Frequently asked questions
What is the difference between Efinopegdutide and Survodutide?
Efinopegdutide: Beat semaglutide on liver fat in a randomised head to head, cutting it 72.7 percent against 42.3 percent, while the weight difference was not significant. Adding glucagon does something to the liver that GLP-1 alone does not. Survodutide: An investigational once-weekly GLP-1 and glucagon receptor dual agonist studied for obesity and metabolic liver disease.
Which has stronger research evidence, Efinopegdutide or Survodutide?
This database does not grade compounds. It counts what was run in people: 3 of the 3 studies cited on the Efinopegdutide profile were human work, against 3 of 3 for Survodutide. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Efinopegdutide and Survodutide FDA-approved?
Efinopegdutide: Investigational. Not approved. Licensed to Merck, originally from Hanmi, and previously carried Johnson and Johnson and Hanmi identifiers.. Survodutide: Investigational, not FDA-approved.
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.